Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2016 02:04 ET | Source: Biofrontera AG

Biofrontera AG: Biofrontera Reports Full Year 2015 Financial Results

LEVERKUSEN, Germany, April 15, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, today reported its full year 2015 financial results for the year ended 31...
April 07, 2016 08:06 ET | Source: Biofrontera AG

Biofrontera AG: Notice of Annual Results 2016

LEVERKUSEN, Germany, April 7, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (AIM:B8F), the specialist for sun-induced skin cancer, will be announcing its financial results for the twelve-month period ended...
April 04, 2016 07:04 ET | Source: Biofrontera AG

Biofrontera Announces NDA Progress Update for BF-200 ALA

FDA issued suggested labeling for BF-200 ALA for treatment of actinic keratosis (AK) FDA has not requested any further data NDA on track LEVERKUSEN, Germany, April 4, 2016 (GLOBE...
February 16, 2016 11:57 ET | Source: Biofrontera AG

Biofrontera AG: Biofrontera AG resolves on capital increase

Leverkusen, Germany, Feb. 16, 2016 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the Supervisory Board, to increase the...
February 11, 2016 10:37 ET | Source: Biofrontera AG

Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer

LEVERKUSEN, Germany, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presents data from three pivotal Phase III trials for its lead drug...